Matrix metalloproteinase-responsive melanin nanoparticles utilize live neutrophils for targeted high-risk plaque detection and atherosclerosis regression
Source abstract
Abstract
Abrupt rupture of atherosclerotic plaque is the predominant contributor to acute cardiovascular events. It is of clinical importance to effectively identify and inhibit high-risk plaque progression. However, this remains a major challenge due to the inadequate targeting of theranostic agents to atherosclerotic lesions. Herein, we utilize live neutrophils to encapsulate melanin-based theranostics (termed MNPpep-Gd) to enhance their plaque targeting, leveraging the inherent inflammatory tropism of neutrophils in atherosclerosis progression. The MNPpep-Gd are fabricated using the water-insoluble gadolinium-chelated melanin nanoparticle modified with a detachable polyethylene glycol (PEG) segment via a matrix metalloproteinase (MMP)-cleavable peptide linker. Our work demonstrated that overexpressed MMP in high-risk plaques can induce an increase in particle size and prolonged retention time of the MNPpep-Gd nanoprobe in lesions, making it a highly efficient contrast agent for magnetic resonance (MR) and photoacoustic (PA) dual-modal imaging atherosclerotic plaque. Concurrently, the melanin nanoparticles function as a therapeutic agent by scavenging multiple toxic reactive oxygen species (ROS), inhibiting the pro-inflammatory cytokines expression, and significantly reducing the foam cell formation. As a result, NE/MNPpep remarkably alleviates atherosclerosis progression by a 24.7 % reduction for plaque area in ApoE-/- mice. Immunohistochemical analysis confirmed that NE/MNPpep treatment significantly reduced the macrophage content by 21.3 % and lipid burden by 15.6 % in plaques. In conclusion, our innovative nanoagent actively targets atherosclerotic sites, offers a noninvasive approach for identifying high-risk atherosclerotic plaques, and significantly contributes to the alleviation of lesion development in ApoE-/- mice. STATEMENT OF SIGNIFICANCE: Effective identification and inhibition of high-risk plaque progression hold clinical importance. However, it remains a major challenge due to the insufficient targeting of theranostic agents to plaques. Herein, a biomimetic nanoplatform is developed to actively target atherosclerosis plaque with the assistance of neutrophils, thereby minimizing off-target effects. Then, overexpressed MMP2 in high-risk plaques trigger the aggregation of hydrophobic Gd3+-labeled melanin nanoparticles, enhancing both MRI/PAI intensities for precise diagnosis. Additionally, the native antioxidant activity of melanin reduces inflammatory level, alleviates oxidative damage, and inhibits plaque progression in ApoE-/- mice. This study offers valuable insights for accurate plaque assessment and provides effective guidance for subsequent management strategies.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Atherosclerosis and Cardiovascular Diseases · Neutrophil, Myeloperoxidase and Oxidative Mechanisms · Protease and Inhibitor Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (48)
Show source-provided references
1. Atherosclerosis: recent developments10.1016/j.cell.2022.04.004 ↗
2. Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research10.1038/s41569-022-00769-8 ↗
3. Vulnerable plaque imaging10.1053/j.semnuclmed.2022.08.009 ↗
4. Targeting inflammation in atherosclerosis - from experimental insights to the clinic10.1038/s41573-021-00198-1 ↗
5. Anti-inflammatory therapeutics for the treatment of atherosclerosis10.1038/nrd3444 ↗
6. Reactive oxygen species scavenging and inflammation mitigation enabled by biomimetic prussian blue analogues boycott atherosclerosis10.1186/s12951-021-00897-2 ↗
7. Small molecule-assisted assembly of multifunctional ceria nanozymes for synergistic treatment of atherosclerosis10.1038/s41467-022-34248-y ↗
8. Natural antioxidant-based nanodrug for atherosclerosis treatment10.1002/smll.202303459 ↗
9. Matrix metalloproteinases as biomarkers of atherosclerotic plaque instability10.3390/ijms21113946 ↗
10. Inflammation-targeted gold nanorods for intravascular photoacoustic imaging detection of matrix metalloproteinase-2 (MMP(2)) in atherosclerotic plaques10.1016/j.nano.2016.02.016 ↗
11. Targeting the microenvironment of vulnerable atherosclerotic plaques: an emerging diagnosis and therapy strategy for atherosclerosis10.1002/adma.202110660 ↗
12. Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis10.1186/s12951-022-01279-y ↗
13. Magnetic dialdehyde starch as green support for the growth of hyaluronic acid terminated covalent organic framework: a pH-controlled daunorubicin delivery system with inherent antibacterial feature10.1016/j.eurpolymj.2023.112428 ↗
14. M. Pooresmaeil, H. Namazi, Surface Modification of Magnetic Nanoparticles For Biomaterials, 1st Edition ed. 2024.10.1201/9781003429920-24 ↗
15. A matrix-metalloproteinase-responsive hydrogel system for modulating the immune microenvironment in myocardial infarction10.1002/adma.202209041 ↗
16. Melanin-based immunoregulatory nanohybrids enhance antitumor immune responses in breast cancer mouse model10.1021/acsnano.3c02287 ↗
17. Intrinsically bioactive manganese-eumelanin nanocomposites mediated antioxidation and anti-neuroinflammation for targeted theranostics of traumatic brain injury
18. Biosynthesis of melanin nanoparticles for photoacoustic imaging guided photothermal therapy10.1002/smll.202205343 ↗
19. Melanin-gelatin nanoparticles with both EPR effect and renal clearance for PA/MRI dual-modal imaging of tumors10.1016/j.msec.2022.112718 ↗
20. Matrix metalloproteinase-initiated aggregation of melanin nanoparticles as highly efficient contrast agent for enhanced tumor accumulation and dual-modal imaging10.1039/D0TB01651A ↗
21. Natural melanin/alginate hydrogels achieve cardiac repair through ROS scavenging and macrophage polarization
22. Natural cell patches: melanin nanoparticles for MR imaging-guided antiatherosclerosis therapy via attenuating macrophage pyroptosis
23. Molecular imaging of matrix metalloproteinase-2 in atherosclerosis using a smart multifunctional PET/MRI nanoparticle10.2147/IJN.S385679 ↗
24. Impact of matrix metalloproteinases on atherosclerosis10.2174/1389450115666140211115805 ↗
25. ROS responsive nanoparticles loaded with lipid-specific AIEgen for atherosclerosis-targeted diagnosis and bifunctional therapy10.1016/j.biomaterials.2022.121734 ↗
26. Biomimetic-coated nanoplatform with lipid-specific imaging and ROS responsiveness for atherosclerosis-targeted theranostics10.1021/acsami.1c08552 ↗
27. Cellular vehicles based on neutrophils enable targeting of atherosclerosis10.1021/acs.molpharmaceut.9b00342 ↗
28. Neutrophils as regulators of cardiovascular inflammation10.1038/s41569-019-0326-7 ↗
29. Neutrophil microvesicles drive atherosclerosis by delivering miR-155 to atheroprone endothelium10.1038/s41467-019-14043-y ↗
30. Immunology. Neutrophil-macrophage communication in inflammation and atherosclerosis10.1126/science.aac7801 ↗
31. Cell-based drug delivery systems and their in vivo fate10.1016/j.addr.2022.114394 ↗
32. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence10.1038/nnano.2017.54 ↗
33. MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma10.1038/s41467-018-07250-6 ↗
34. Novel insight on the role of macrophages in atherosclerosis: focus on polarization, apoptosis and efferocytosis10.1016/j.intimp.2022.109260 ↗
35. Optical/MRI dual-modality imaging of M1 macrophage polarization in atherosclerotic plaque with MARCO-targeted upconversion luminescence probe10.1016/j.biomaterials.2019.119378 ↗
36. Rational design of a double-locked photoacoustic probe for precise In vivo imaging of cathepsin B in atherosclerotic plaques10.1021/jacs.3c04981 ↗
37. Lipid droplet-hitchhiking probe creates Trojan foam cells for fluorescence/photoacoustic imaging of atherosclerotic plaques10.1016/j.bios.2022.114613 ↗
38. Ratiometric semiconducting polymer nanoparticle for reliable photoacoustic imaging of pneumonia-induced vulnerable atherosclerotic plaque in vivo10.1021/acs.nanolett.1c01359 ↗
39. Shape-dependent cellular behaviors and relaxivity of iron oxide-based T(1) MRI contrast agents10.1039/C6NR06158C ↗
40. Ultrathin iron oxide nanowhiskers as positive contrast agents for magnetic resonance imaging10.1002/adfm.201403436 ↗
41. Inflammation resolution: implications for atherosclerosis10.1161/CIRCRESAHA.121.319822 ↗
42. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention10.1038/s41392-022-00955-7 ↗
43. Advances in the pathogenesis and prevention of contrast-induced nephropathy10.1016/j.lfs.2020.118379 ↗
44. Metal nanoparticles in atherosclerosis: applications and potential toxicity10.5101/nbe.v7i3.p111-127 ↗
45. Targeting theranostics of atherosclerosis by dual-responsive nanoplatform via photoacoustic imaging and three-in-one integrated lipid management10.1002/adma.202206129 ↗
46. Melanin nanoparticles alleviate sepsis-induced myocardial injury by suppressing ferroptosis and inflammation
47. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis10.1038/s41569-021-00629-x ↗
48. Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment10.1038/s41565-024-01687-1 ↗